Off-campus WSU users: To download campus access dissertations, please use the following link to log into our proxy server with your WSU access ID and password, then click the "Off-campus Download" button below.

Non-WSU users: Please talk to your librarian about requesting this thesis through interlibrary loan.

Access Type

WSU Access

Date of Award

January 2022

Degree Type


Degree Name



Pharmaceutical Sciences

First Advisor

Navnath Gavande


Pancreatic ductal adenocarcinoma (PDAC), often known as pancreatic cancer, is one of the main causes of cancer-related fatalities in the Western world because of early metastases, advanced disease presentation, and a typically relatively low response to chemotherapy or radiotherapy. Gemcitabine remains a cornerstone of PDAC treatment in all stages of the disease despite suboptimal clinical effects primarily caused by molecular mechanisms limiting its cellular uptake and activation and overall efficacy, as well as the development of chemoresistance within weeks of treatment initiation. Gemcitabine resistance in PDAC is currently being investigated using a variety of cutting-edge therapeutic approaches, such as chemical modifications of the gemcitabine molecule that result in a variety of new prodrugs and new entrapment designs of gemcitabine in colloidal systems, such as nanoparticles and liposomes. Several of these techniques are claimed to be more efficient than the parent gemcitabine molecule when tested in cellular systems and in vivo in mouse tumour model systems. The chemical composition of analogues of gemcitabine was altered at Dr. Gavande's lab. Then, under the direction of Dr. Mohammed Teiama, we had the chance to make liposomes while working with Dr. Iyer. In vitro biological testing was performed on both these analogues and the liposomal preparations. Therefore, the goal of all these results was to overcome gemcitabine's chemoresistance in pancreatic cancer.

Off-campus Download